MAIN ARTICLE
Why approval matters for a rare disease
Gaucher disease arises when an inherited enzyme deficiency prevents the normal breakdown of certain fatty materials. Accumulation can affect the spleen, liver, blood and bones. In type 3, neurological manifestations add a difficult dimension: patients may experience problems with balance, eye movements, speech, coordination and cognitive function. Symptoms and their progression vary considerably, complicating both treatment and assessments of benefit.
For years, enzyme replacement treatment has helped address complications outside the central nervous system. Its importance is undisputed, but large enzyme molecules generally cannot penetrate the blood-brain barrier in sufficient amounts to treat neurological disease. Families have therefore faced a frustrating divide between improvements in general medical care and the persistent risk of progressive nervous-system problems. Infilbray addresses that longstanding therapeutic gap.
A different route into the brain
Venglustat inhibits glucosylceramide synthase, an enzyme involved in manufacturing the lipids that build up in Gaucher disease. Rather than supplying missing enzyme, as imiglucerase therapy does, it reduces production of the relevant fatty material.
















